Shanghai MicroPort Endovascular MedTech Group Co Ltd
SSE:688016
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
79.81
206.98
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Shanghai MicroPort Endovascular MedTech Group Co Ltd
Shanghai MicroPort Endovascular MedTech Group Co Ltd
Cash from Operating Activities
Shanghai MicroPort Endovascular MedTech Group Co Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shanghai MicroPort Endovascular MedTech Group Co Ltd
SSE:688016
|
Cash from Operating Activities
¥558.3m
|
CAGR 3-Years
37%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
|
Cash from Operating Activities
¥2.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Autobio Diagnostics Co Ltd
SSE:603658
|
Cash from Operating Activities
¥1.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Winner Medical Co Ltd
SZSE:300888
|
Cash from Operating Activities
¥1.1B
|
CAGR 3-Years
-39%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Cash from Operating Activities
¥1.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Intco Medical Technology Co Ltd
SZSE:300677
|
Cash from Operating Activities
¥775.5m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
Shanghai MicroPort Endovascular MedTech Group Co Ltd
Glance View
Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, production, and sale of aortic and peripheral vascular interventional medical devices. The company is headquartered in Shanghai, Shanghai and currently employs 660 full-time employees. The company went IPO on 2019-07-22. The firm's main products include the aortic stent graft system for aortic minimally invasive interventional procedures, the intraoperative stent system for open surgery, as well as the peripheral vascular stent system and peripheral balloon dilatation catheters for the treatment of peripheral vascular diseases. The firm mainly distributes its products to the domestic market.
See Also
What is Shanghai MicroPort Endovascular MedTech Group Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
558.3m
CNY
Based on the financial report for Dec 31, 2023, Shanghai MicroPort Endovascular MedTech Group Co Ltd's Cash from Operating Activities amounts to 558.3m CNY.
What is Shanghai MicroPort Endovascular MedTech Group Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
39%
Over the last year, the Cash from Operating Activities growth was 67%. The average annual Cash from Operating Activities growth rates for Shanghai MicroPort Endovascular MedTech Group Co Ltd have been 37% over the past three years , 39% over the past five years .
You don't have any saved screeners yet
